Type 2(non-insulin dependent) diabetes mellitus
Conditions
Interventions
Administration of sodium glucose transporter-2(SGLT-2) inhibitor, Luseogliflozin, and dose of Luseogliflozin is 25mg once a daily before breakfast, administration period of Luseogliflozin is 12wweks.
Sponsors
Kitasato University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 (non-insulin dependent) diabetes patients who are controlled in diet and exercise, and glycated Hb(HbA1c) is 7.0% or above and 10.0% or below.
Exclusion criteria
Exclusion criteria: 1. A patient suffering from acute disease 2. In case of malignacy 3. Renal dysfunction (estimeted GFR <60ml/min) 4. Liver dysfunction (AST >100U/l, ALT >100U/l) 5. Pregnant or possibility of pregnant 6. Lactating mothers 7. A patient suffering from endocrine disorders 8. A patient administrated any drugs affect glucose metabolism 9. Diabetic patients who have taken any hypoglycemic agents include SGLT-2 inhibitor in proximate 6 months 10.A patient undergoing or having history of treatment for ischemic heart disease 11.Chronic heart failure (NYHA class 2 or worse) 12.A patient undergoing or having history of treatment for cerebro-vascular disease 13.A patient undergoing or multiple (3 times or more) history of urinary or genital tract infection 14.A patient accompanied with severe diabetic retinopathy, nephropathy, neuropathy 15.A patient in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia 16.Taking diuretics 17.Correspond to contraindication of Luseogliflozin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The alternation in glucagon secretion pattern by dietary intake before and after 12 weeks administration of sodium glucose transporter-2(SGLT-2) inhibitor. | — |
Countries
Japan
Contacts
Public ContactRaishi Ichikawa
Kitasato University, School of Medicine Department of diabetes , endocrinology and metabolism
Outcome results
None listed